AzTrials
AzTrials

GrowthFormulaNCT01158352

Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children

A study testing Nutritional supplementation formula in people with Growth and Low Weight, run by Rabin Medical Center at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study design: Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments: 1. Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and… Read more about this study

Who is it for?
Ages 3 to 8 years
Conditions the study is for
Growth, Low Weight, Low Height
What is being tested?
Nutritional supplementation formula
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteIsrael
Study dates
Nov 2010to Nov 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 8 years
  • All sexes
  • No healthy volunteers
  • Child

Inclusion Criteria for participants at the intervention group (segments 1\&2):

  1. Girls aged 3-7 years old and boys aged 3-8 years old
  2. Prepubertal - tanner stage 1
  3. Height, weight and BMI < 10th percentile for age and gender
  4. Availability of growth velocity data for at least 4 months prior to study entry.
  5. Signing inform consent forms

Exclusion Criteria for participants at the intervention group (segments 1):

  1. Diagnosis of GH Deficiency or treatment with GH
  2. Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
  3. Any known gastrointestinal problem including absorption problems
  4. Any known organic reason for slow growth
  5. Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth.

Inclusion Criteria for participants at the control group (segments 2):

  1. Girls aged 3-8 years old and boys aged 3-9 years old
  2. Prepubertal - tanner stage 1
  3. Height ≥ 25th percentile for age and gender
  4. Proper proportion between weight and height- 5th ≤ BMI ≤ 85th
  5. Signing inform consent forms

Exclusion Criteria for participants at the control group (segments 2):

  1. Diagnosis of GH Deficiency or treatment with GH
  2. Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
  3. Any known gastrointestinal problem including absorption problems
  4. Any known organic reason for slow growth
  5. Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth
  6. Children with growth faltering during the previous year

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Schneider Children's Medical center

    Petaach-Tikva, 49202

Other trials in Israel

About this study

Official title: Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children

Study design:

Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:

Read more
  1. Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
  2. Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight

Segment 1

Population:

200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.

Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.

Methods:

Randomization \& Blinding:

Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.

Treatment:

Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.

Treatment duration:

The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.

Study Schedule:

Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:

  1. Demographic data, medical history and growth data (month 0): Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.
  2. Nutritional assessment
  3. Anthropometric assessment (months 0, 3, 6, 9 12):
  4. Height without shoes
  5. Length
  6. Weight with light cloths and without shoes
  7. MAC
  8. Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
  9. Body composition assessment using the method of bioelectrical impedance
  10. Laboratory parameters (months 0, 6 and 12):
  11. Sleeping Questionaire

Segment 2:

86 subjects and controls will be recruited to segment 2 of the proposed study

Population:

Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study

Control group 1:

Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.

Control group 2:

Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile

Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.

Being tested
Nutritional supplementation formula, Placebo Comparator
Keywords
Growth, Low weight, Low height, Nutritional Formula
Medical subject headings
Thinness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nutritional supplementation formulaDietary supplement

    Nutritional supplementation formula

  • Placebo ComparatorDietary supplement

    Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals

Study groups in NCT01158352
Study groupRoleWhat they receive
Nutritional supplemntation formulaExperimentalNutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
Receives: Dietary Supplement: Nutritional supplementation formula
Placebo ComparatorPlacebo comparatorPlacebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
Receives: Dietary Supplement: Placebo Comparator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Height SDS (standard deviation score)

    standard deviation score of patient's height at 12 months

    Measured: At 12 months

Secondary outcomes (8)
  1. Weight SDS (standard deviation score)

    Standard deviation score of patient's weight at 12 months

    Measured: At 12 months

  2. Weight/Height SDS (standard deviation score)

    Standard deviation score of patient's Weight / Height ratio at 12 months

    Measured: At 12 months

  3. BMI SDS (standard deviation score)

    standard deviation score of patient's BMI at 12 months

    Measured: At 12 months

  4. Growth Velocity

    Measured: At 12 months

  5. 5.Sleeping Questionaire

    Measured: At 12 months

  6. Child Eating Behaviour Questionaire (CEBQ)

    Measured: At 12 months

  7. 3-day food diary

    Measured: At 12 months

  8. Physical activity questionnaire

    Measured: At study entry

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2010 (estimated)
  2. Study startNov 2010
  3. Primary completionNov 2014
  4. Study completionNov 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01158352
Sponsor's protocol ID
rmc005547ctil
Acronym
Formula
Status last verified
Nov 2014
First submitted
27 Jun 2010
Last updated
7 Nov 2014
Results posted
No
Data monitoring committee
No

Publications

  • Yackobovitch-Gavan M, Lebenthal Y, Lazar L, Shalitin S, Demol S, Tenenbaum A, Shamir R, Phillip M. Effect of Nutritional Supplementation on Growth in Short and Lean Prepubertal Children after 1 Year of Intervention. J Pediatr. 2016 Dec;179:154-159.e1. doi: 10.1016/j.jpeds.2016.08.100. Epub 2016 Sep 30.

    PubMed 27697330
  • Lebenthal Y, Yackobovitch-Gavan M, Lazar L, Shalitin S, Tenenbaum A, Shamir R, Phillip M. Effect of a nutritional supplement on growth in short and lean prepubertal children: a prospective, randomized, double-blind, placebo-controlled study. J Pediatr. 2014 Dec;165(6):1190-1193.e1. doi: 10.1016/j.jpeds.2014.08.011. Epub 2014 Sep 17.

    PubMed 25241181

Questions about this trial

What is this clinical trial studying?

A study testing Nutritional supplementation formula in people with Growth and Low Weight, run by Rabin Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Height SDS (standard deviation score) (time frame: At 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01158352, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in